Outpatient Supportive Care Following Chemotherapy for Acute Myeloblastic Leukemia

References

• Ruiz-Arguelles G. J., Apreza-Molina Ma. G., Aleman-Hoey D. D., Gomez-Almaguer D., Marin-Lopez A., Mercado-Diaz L. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. European Journal of Haematology 1995; 54: 18–20
   PubMed Web of Science ®Google Scholar
• Gillis S., Dann E. J., Rund D. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. American Journal of Hematology 1996; 51: 26–31
   PubMed Web of Science ®Google Scholar
• Girmenia C., Latagliata R., Tosti S., Morano S. G., Celesti F., Coppola L., Spadea A., Breccia M., Battistini R., Tafuri A., Cimino G., Mandelli F., Alimena G. Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. Leukemia 1999; 13: 514–517
   PubMed Web of Science ®Google Scholar
• Wade C. J., Schimpff S. C., Hargadon M. S., Former C. L., Young V. M., Weirnik P M. A comparison of trimethoprim-sulfamethoxazole plus nystatin in the prevention of infections in acute leukemia. New England Journal of Medicine 1981; 304: 1057–1062
   PubMed Web of Science ®Google Scholar
• Estey E., Maksymiuk A., Smith T., Fainstein V., Keating M., McCredie K. B., Freireichet E. J., Bodey G P. Infection prophylaxis in acute leukemia: comparative effectiveness of sulfamethoxazole and trimathoprim, ketoconazole, and a combination of the two. Archives of Internal Medicine 1984; 144: 1562–1568
   PubMed Web of Science ®Google Scholar
• Weiser B., Lange M., Fialk M. A., Singer C., Szatrowski T. H., Armstrong D. Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: a controlled trial. Annals of Internal Medicine 1981; 95: 436–438
   PubMed Web of Science ®Google Scholar
• Karthaus M., Carratala J., Jurgens H., Ganser A. New strategies in the treatment of infectious complications in Haematology and Oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia. Chemotherapy 1998; 44: 427–435
   PubMed Web of Science ®Google Scholar
• Bennet J. M., Catovky D., Daniel M. T., Flandrin G., Galton D. A.G., Gralnick H. R., Sultan C. French American British Cooperative Group. Proposals for the classification of acute leukemia. British Journal of Haematology 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bennet J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A.G., Gralnick H. R., Sultan C. French American British Cooperative Group. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Annals of Internal Medicine 1985; 103: 460–465
   PubMed Web of Science ®Google Scholar
• Bennet I. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A.G., Gralnick H. R., Sultan C. French American British Cooperative Group. Proposals for the recognition of minimally differentiated acute myeloid leukemia. British Journal of Haematology 1991; 78: 325–329
   PubMed Web of Science ®Google Scholar
• Rebulla P., Finazzi G., Marangoni F., Avvisati G., Gugliotta L., Tognoni G., Barbui T., Mandelli F., Sitchia G. The threshold for prophylactic platelet transfusions in adults with acule myeloid leukemia. The New England Journal of Medicine 1997; 337: 1870–1875
   PubMed Web of Science ®Google Scholar
• Huges W. T., Armstrong D., Bodey G. P., et al. From the Infectious Diseases Society of America: guidelines for the use of antimicrobial agents in nuetropenic patients with unexplained fever. Journal of Infectious Diseases 1990; 161: 381–396
   PubMed Web of Science ®Google Scholar
• Hughes W. T., Armstrong D., Bodey G. P., Brown A. E., Edwards J. E., Feld R., Pizzo P., Rolston K. V.I., Shenep J. L., Young L S. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases 1997; 25: 551–573
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Reece D. E., Shepherd J. D., Barnett M. J., Brown R. A., Frei-Lahr D. A., Klingemann H. G., Bolwell B. J., Spinelli J. J., Herzig R. H., Herzig G P. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429–1435
   PubMed Web of Science ®Google Scholar
• Wiernik P. H., Banks P. L.C., Case D. C., Arlin Z. A., Perlman P. O., Todd M. B., Ritch P. S., Enck R. E., Weitberg A B. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–319
   PubMed Web of Science ®Google Scholar
• Favre G., Fopp M., Gmur J., Tichelli A., Tobler A., Schatzmann E., Gratwohl A. Factors associated with transfusion requirements during treatment for acute myelogenous leukemia. Annals of Hematology 1993; 67: 153–160
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles G. J., Lobato-Mendizabal E., Delgado-Lamas J. L., Gomez-Almaguer D. All trans-retinoic acid decreases early mortality in patients with promyelocytic leukemia and can be given entirely on an outpatient basis. American Journal of Hematology 1999; 62: 139–143
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D., Ruiz-Arguelles G. J., Ruiz-Arguelles A., Gonzalez-Llano O., Cantu O. E., Hernandez N E. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplantation 2000; 25: 131–133
   PubMed Web of Science ®Google Scholar